Arbutus Biopharma Corpora... (ABUS)
Arbutus Biopharma Statistics
Share Statistics
Arbutus Biopharma has 191.48M shares outstanding. The number of shares has increased by 1.46% in one year.
| Shares Outstanding | 191.48M |
| Shares Change (YoY) | 1.46% |
| Shares Change (QoQ) | 1.05% |
| Owned by Institutions (%) | 54.9% |
| Shares Floating | 148.63M |
| Failed to Deliver (FTD) Shares | 615 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 6.64M, so 3.5% of the outstanding shares have been sold short.
| Short Interest | 6.64M |
| Short % of Shares Out | 3.5% |
| Short % of Float | 4.5% |
| Short Ratio (days to cover) | 7.07 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -7.13. Arbutus Biopharma's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -7.13 |
| PS Ratio | 98.35 |
| Forward PS | 3.8 |
| PB Ratio | 6.23 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Arbutus Biopharma Corporation has an Enterprise Value (EV) of 397.34M.
| EV / Earnings | -5.68 |
| EV / Sales | 64.39 |
| EV / EBITDA | -5.81 |
| EV / EBIT | -5.21 |
| EV / FCF | -6.13 |
Financial Position
The company has a current ratio of 8.15, with a Debt / Equity ratio of undefined.
| Current Ratio | 8.15 |
| Quick Ratio | 8.15 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | - |
| Cash Flow / Debt | null |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is -77.36%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | -77.36% |
| Revenue Per Employee | $140,250 |
| Profits Per Employee | $-1,589,090.91 |
| Employee Count | 44 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 38.1% in the last 52 weeks. The beta is 1.93, so Arbutus Biopharma's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | 38.1% |
| 50-Day Moving Average | 3.35 |
| 200-Day Moving Average | 3.59 |
| Relative Strength Index (RSI) | 57.44 |
| Average Volume (20 Days) | 879.38K |
Income Statement
In the last 12 months, Arbutus Biopharma had revenue of 6.17M and earned -69.92M in profits. Earnings per share was -0.38.
| Revenue | 6.17M |
| Gross Profit | 6.17M |
| Operating Income | -76.32M |
| Net Income | -69.92M |
| EBITDA | -68.4M |
| EBIT | -76.32M |
| Earnings Per Share (EPS) | -0.38 |
Balance Sheet
The company has 36.33M in cash and 1.29M in debt, giving a net cash position of 35.04M.
| Cash & Cash Equivalents | 36.33M |
| Total Debt | 1.29M |
| Net Cash | 35.04M |
| Retained Earnings | 0 |
| Total Assets | 140.44M |
| Working Capital | 113.85M |
Cash Flow
In the last 12 months, operating cash flow was -64.85M and capital expenditures 0, giving a free cash flow of -64.85M.
| Operating Cash Flow | -64.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -64.85M |
| FCF Per Share | -0.35 |
Margins
Gross margin is 100%, with operating and profit margins of -1.24K% and -1.13K%.
| Gross Margin | 100% |
| Operating Margin | -1.24K% |
| Pretax Margin | -1.13K% |
| Profit Margin | -1.13K% |
| EBITDA Margin | -1.11K% |
| EBIT Margin | -1.24K% |
| FCF Margin | -1.05K% |
Dividends & Yields
ABUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.92% |
| FCF Yield | -9.72% |
Analyst Forecast
The average price target for ABUS is $5, which is 43.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 43.7% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Nov 4, 2010. It was a backward split with a ratio of 1:5.
| Last Split Date | Nov 4, 2010 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -3 |
| Piotroski F-Score | 3 |